|
EQS-News: Gerresheimer AG
/ Key word(s): Half Year Report/Quarterly / Interim Statement
Gerresheimer continues dynamic growth in first half of 2023
Duesseldorf, July 6, 2023. Gerresheimer, an innovative provider of systems and solutions and a global partner for the pharma and biotech industries, has continued its profitable growth, posting strong results for the first half of the year. Revenues grew organically, without foreign exchange rate effects, by 16.6% to reach EUR 957.4m. Adjusted EBITDA was EUR 185.2m. Following the successful realignment of its product mix, Gerresheimer benefited substantially from global megatrends in the pharma and biotech markets. Gerresheimer offers a broad portfolio of solutions, especially for biopharmaceuticals (including the new medications for treating obesity based on glucagon-like peptide 1, or GLP-1), and has already succeeded in securing long-term orders. The company is currently expanding its production capacities in Europe, the United States, and Mexico to accommodate its growth plans, with a focus on medical systems such as syringes, pens, and auto-injectors, as well as high-value solutions. “As a result of our focus on innovation, excellence, and sustainability, we are today the strategic partner of choice for the global pharma and biotech industry,” said Dietmar Siemssen, CEO of Gerresheimer AG. “We benefit from demand for both containment solutions and innovative drug delivery solutions for new biopharmaceuticals. We have the right systems, solutions, and services and are investing today in the profitable growth of tomorrow.” Plastics & Devices: High demand for containment solutions, inhalers, and pens The Plastics & Devices Division generated revenues of EUR 494.1m in the first half of 2023 (H1 2022: EUR 414.0m) representing an organic increase of 18.2% (excluding foreign exchange rate effects). The demand for containment solutions made from plastic and for medical devices, especially inhalers and pens, played a particularly important role in the excellent performance. Thanks to organic growth of 25.1%, adjusted EBITDA was significantly higher year on year. The adjusted EBITDA margin improved by 110 basis points to 23.5% (H1 2022: 22.4%). The increase in profitability is mainly attributable to an improved product mix. Primary Packaging Glass benefits from positive market momentum The Primary Packaging Glass Division generated a 15.5% increase in revenues in the first half of 2023 to EUR 461.7m (H1 2022: EUR 399.9m). The division benefited from strong performances in both the Moulded Glass and Tubular Glass Business Units. Demand for high-value solutions remained robust. Adjusted EBITDA rose sharply by 25.2% in organic terms compared to the same period in the prior year. The adjusted EBITDA margin improved by 120 basis points to 19.5% (H1 2022: 18.3%). The increase was due to the good overall performance of the business units and the improved product mix. Outlook confirmed Gerresheimer expects the positive business performance to continue in the second half of 2023 and confirms its guidance for the full year. Guidance for FY 2023 (for group level, currency-adjusted):
Medium-term guidance (for group level, currency-adjusted)
The Half-Year Financial Report is available on the Gerresheimer website here:
Contact Gerresheimer AG Media Investor Relations
Key Figures Gerresheimer (group)
06.07.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Gerresheimer AG |
| Klaus-Bungert-Str. 4 | |
| 40468 Düsseldorf | |
| Germany | |
| Phone: | +49-(0)211/61 81-314 |
| Fax: | +49-(0)211/61 81-121 |
| E-mail: | carolin.nadilo@gerresheimer.com |
| Internet: | http://www.gerresheimer.com |
| ISIN: | DE000A0LD6E6 |
| WKN: | A0LD6E |
| Indices: | MDAX (Aktie) |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1673579 |
| End of News | EQS News Service |
|
|
1673579 06.07.2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
